Tag - ADMS

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Executive Moves

Adamas Pharma names Neil McFarlane as CEO

Neil McFarlane Adamas Pharmaceuticals (NASDAQ:ADMS) has appointed Neil McFarlane as CEO and a member of its board, effective Sept. 16. Gregory Went, Adamas’ founder, chairman and CEO, will transition to a strategic...

September 13, 2019

Tag - ADMS

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Adamas Pharma names Neil McFarlane as CEO

General

More